Related Experiment Video

Updated: Oct 22, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.3K

Moving Towards Targeted Therapies for Triple-Negative Breast Cancer

Jodi A Kagihara1, Elena Shagisultanova1, Anosheh Afghahi1

  • 1Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, United States of America.

Current Breast Cancer Reports
|August 30, 2021
PubMed
Abstract

Insights

Targeted therapies are improving outcomes for Triple-negative breast cancer (TNBC), a subtype with poor prognosis. Approved agents like PARP inhibitors and PD-L1 inhibitors offer new hope for patients with TNBC.

Area of Science:

  • Oncology
  • Medical Research
  • Clinical Trials

Background:

  • Triple-negative breast cancer (TNBC) represents 15-20% of breast cancer cases.
  • TNBC is linked to poorer clinical outcomes, including higher metastatic recurrence and lower overall survival.
  • Historically, cytotoxic chemotherapy has been the primary treatment for TNBC.

Purpose of the Study:

  • To review targets of interest in TNBC.
  • To discuss approved targeted agents and their supporting clinical trial data.
  • To examine ongoing clinical trials for novel targeted agents in TNBC treatment.

Main Methods:

  • Literature review of clinical trials and approved therapies for TNBC.
  • Analysis of current research on targeted agents in TNBC treatment.
  • Synthesis of data on novel targeted agents under investigation.

Main Results:

  • Several targeted therapies are now approved for select TNBC patients.
  • Approved agents include PARP inhibitors (olaparib, talazoparib), PD-L1 inhibitors (atezolizumab), and a Trop-2 targeting antibody-drug conjugate (sacituzumab govitecan-hziy).
  • These approvals mark a significant advancement from traditional chemotherapy.

Conclusions:

  • Numerous novel targeted agents are under investigation as monotherapy and in combination regimens.
  • Promising results suggest these agents may substantially enhance patient outcomes in TNBC.
  • Ongoing research aims to further refine and expand targeted treatment options for TNBC.
Keywords:
immunotherapynovel agentstargeted therapiestriple-negative breast cancer

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
771
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K